Kura Oncology (FRA:KUR) E10: €-1.89 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:KUR Kura Oncology Inc FRA:KUR
36 GF Score
Price €9.84
! 7 Warning Signs
View Full Analysis

What is Kura Oncology E10?

Kura Oncology FRA:KUR -5.38% 36 E10 is €-1.89 as of Mar. 2026. GuruFocus rates FRA:KUR with a GF Score™ of 36/100. The stock has 7 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Kura Oncology's adjusted earnings per share data for the three months ended in Mar. 2026 was €-0.718. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €-1.89 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2026-07-14), Kura Oncology's current stock price is €9.84. Kura Oncology's E10 for the quarter that ended in Mar. 2026 was €-1.89. Kura Oncology's Shiller PE Ratio of today is .


Kura Oncology  (FRA:KUR) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Kura Oncology E10 Related Terms


Kura Oncology E10 Historical Data

* Premium members only.

The historical data trend for Kura Oncology's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kura Oncology E10 Chart

Kura Oncology Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 -2.12 -1.87

Kura Oncology Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.08 -1.89 -1.87 -1.87 -1.89

FRA:KUR vs REPL, AVTX, SANA: E10 Comparison

For the Biotechnology subindustry, Kura Oncology's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kura Oncology Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kura Oncology's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Kura Oncology's Shiller PE Ratio falls into.


FRA:KUR
36GF Score
Kura Oncology Inc FRA:KUR
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kura Oncology E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Kura Oncology's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.718/330.2130*330.2130
=-0.718

Current CPI (Mar. 2026) = 330.2130.

Kura Oncology Quarterly Data

per share eps CPI Adj_EPS
201606 -0.320 241.018 -0.438
201609 -0.330 241.428 -0.451
201612 -0.360 241.432 -0.492
201703 -0.365 243.801 -0.494
201706 -0.356 244.955 -0.480
201709 -0.319 246.819 -0.427
201712 -0.313 246.524 -0.419
201803 -0.373 249.554 -0.494
201806 -0.385 251.989 -0.505
201809 -0.343 252.439 -0.449
201812 -0.369 251.233 -0.485
201903 -0.327 254.202 -0.425
201906 -0.336 256.143 -0.433
201909 -0.327 256.759 -0.421
201912 -0.351 256.974 -0.451
202003 -0.380 258.115 -0.486
202006 -0.355 257.797 -0.455
202009 -0.357 260.280 -0.453
202012 -0.370 260.474 -0.469
202103 -0.386 264.877 -0.481
202106 -0.423 271.696 -0.514
202109 -0.425 274.310 -0.512
202112 -0.434 278.802 -0.514
202203 -0.445 287.504 -0.511
202206 -0.492 296.311 -0.548
202209 -0.535 296.808 -0.595
202212 -0.463 296.797 -0.515
202303 -0.467 301.836 -0.511
202306 -0.489 305.109 -0.529
202309 -0.469 307.789 -0.503
202312 -0.504 306.746 -0.543
202403 -0.543 312.332 -0.574
202406 -0.548 314.175 -0.576
202409 -0.568 315.301 -0.595
202412 -0.210 315.605 -0.220
202503 -0.610 319.799 -0.630
202506 -0.650 322.561 -0.665
202509 -0.724 324.800 -0.736
202512 -0.786 324.054 -0.801
202603 -0.718 330.213 -0.718

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of €-1.89 mean?
Kura Oncology (FRA:KUR) has a E10 of €-1.89 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Kura Oncology and its competitors.
Is Kura Oncology's E10 too high?
Kura Oncology's current E10 is €-1.89. Overall, Kura Oncology has a GF Score™ of 36/100, reflecting its overall financial health beyond just this single metric.
How does Kura Oncology's E10 compare to REPL and AVTX?
Kura Oncology's E10 of €-1.89 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Biotechnology company?
A good E10 depends on the Biotechnology industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Kura Oncology and its competitors. Kura Oncology's current E10 is €-1.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kura Oncology stock overvalued right now?
Kura Oncology (FRA:KUR) has a current E10 of €-1.89. The current E10 is €-1.89. Kura Oncology's overall GF Score™ is 36/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Kura Oncology (FRA:KUR), the current E10 is €-1.89 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Kura Oncology Business Description

Other Exchanges KURA:USA
Address 4930 Directors Place, Suite 500, San Diego, CA, USA, 92121
Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncology and hematology. Its pipeline includes menin inhibitor ziftomenib for the treatment of acute myeloid leukemia and other hematologic malignancies, as well as additional product candidates such as KO-7246 and darolifarnib being evaluated for solid tumors and other diseases.
36GF Score

Get the complete analysis for FRA:KUR

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€9.84
Price